文献速递甲状腺疾病

第二次放射性碘治疗:对分化型甲状腺癌伴局部区域持续性疾病获益有限

Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer With Locoregional Persistent Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

该研究纳入20年间在某三级医院接受至少两次放射性碘治疗的164例分化型甲状腺癌患者,比较再次治疗前后甲状腺球蛋白和颈部影像。结果显示,结构性持续病患者再次治疗后多稳定或进展,仅生化持续者刺激后甲状腺球蛋白下降;最终仅34.1%无病证据,作者认为获益有限。

要点

  • 再治疗前未手术的114例中53例有结构性病变,41例有数据者中10例进展、5例消退/缩小、26例稳定。
  • 生化持续者61例刺激后甲状腺球蛋白由41.9±56降至24.6±54 ng/mL(P=0.003)。
  • 再治疗前颈部手术的50例刺激后甲状腺球蛋白无实质变化,21例(42%)1-2年后仍有影像学发现。

核心结论

  • 第二次放射性碘治疗对分化型甲状腺癌伴生化或局部区域结构性持续性疾病获益有限。
  • 作者认为需要前瞻性研究来区分哪些患者可能需要重复放射性碘治疗,以避免不必要的暴露。

研究设计与样本

  • 回顾性识别20年间在某三级医院接受至少两次放射性碘治疗的分化型甲状腺癌患者。
  • 共纳入164例患者(103例女性;平均年龄46.6±17岁)。
  • 比较再次治疗前与治疗后1至2年的甲状腺球蛋白水平和颈部影像,并在末次访视时评估。

主要发现

  • 再治疗前未行再次手术的114例中53例有结构性病变;有足够数据的41例中,10例结构性进展、5例消退/缩小、26例稳定。
  • 结构性病变患者刺激后甲状腺球蛋白再治疗前为93.7.1±108 ng/mL,再治疗后为102.2±124 ng/mL(P=NS)。
  • 仅生化持续者61例刺激后甲状腺球蛋白由41.9±56降至24.6±54 ng/mL(P=0.003)。
  • 再治疗前接受颈部手术的50例刺激后甲状腺球蛋白无实质变化;21例(42%)1至2年后仍有影像学发现。
  • 末次随访时,尽管63/164例(38.4%)接受了额外治疗,仅56/164例(34.1%)无病证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Radioactive iodine (RAI) treatment is often indicated after total thyroidectomy in differentiated thyroid cancer (DTC). However, its role in biochemical or locoregional persistent DTC is unclear. We aimed to investigate the effect of a second RAI treatment in patients with incomplete response to initial treatment and no evidence of distant metastases. METHODS: Patients who underwent at least two RAI treatments over a 20-year period at a tertiary hospital were identified. Thyroglobulin levels and neck imaging were compared before and 1 to 2 years after RAI retreatment and evaluated at the last visit. RESULTS: The cohort included 164 patients (103 female; mean age, 46.6 ± 17 years). Of 114 patients retreated without prior reoperation, 53 had structural disease. At 1 to 2 years after RAI retreatment, 10 of the 41 patients with sufficient data had structural progression, 5 resolution/shrinkage, and 26 stable disease. Stimulated thyroglobulin (stTg) measured 93.7.1 ± 108 ng/mL before and 102.2 ± 124 ng/mL after retreatment (P = NS). The other 61 patients had biochemical-only persistence. Their stTg levels decreased from 41.9 ± 56 to 24.6 ± 54 ng/mL (P = 0.003). The 50 patients who underwent neck reoperation before RAI retreatment showed no substantial change in stTg; 21 (42%) still had imaging findings 1 to 2 years later. At final follow-up, despite additional treatment in 63/164 patients (38.4%), only 56/164 (34.1%) had no evidence of disease. CONCLUSIONS: This comprehensive study showed limited benefit of second RAI treatment in DTC patients with biochemical or locoregional structural persistent disease. Prospective studies are needed to distinguish patients for whom repeated RAI may be indicated to avoid unnecessary exposure.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hirsch D, Gorshtein A, Robenshtok E, et al. Second Radioiodine Treatment: Limited Benefit for Differentiated Thyroid Cancer With Locoregional Persistent Disease. J Clin Endocrinol Metab. 2018. PMID: 29126111. doi:10.1210/jc.2017-01790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。